Grail Inc.
http://www.grailbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Grail Inc.
Harbinger Health Raised $140M In Series B To Further Develop First Blood-Based Cancer Test
Harbinger Health has raised a total of $190m since its founding in 2021. Its CEO Stephen Hahn told Medtech Insight in March that the company plans to develop a blood-based cancer test that is affordable, accessible and also more accurate than currently available tests.
FTC’s Khan Addresses PBMs, Amgen-Horizon Merger, At Contentious Congressional Hearing
Republican members of the House Judiciary Committee question FTC policies under Khan’s leadership, including its challenge of the Amgen-Horizon and Illumina-Grail mergers, as well as a proposal to require more information in pre-notification submissions. ‘You’re a bully,’ Representative Issa tells her.
Illumina Creeps Closer To Half-Billion-Dollar Fine
The sequencing giant could be pilloried in Europe and may have to pay a record-breaking fine.
BioBytes: Against A Turbulent Corporate Backdrop, Illumina Touts New AI Gene Analysis Tool
Welcome to In Vivo’s new AI-focused blog, BioBytes, providing news and insight on the growing role of artificial intelligence in biopharma. In this post, Illumina’s new large language model-based gene analysis tool could help drive uptake of its products.
Company Information
- Industry
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- GRAILBio Cirina Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice